DiabetesCOMMITNCT00676741
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
An observational study of Diabetes and Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 1 site in Slovakia.
Trial summary
The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes. Full acronym for this study: COMMIT - CLEAN SWITCH Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes, Diabetes Mellitus, Type 2
- What is being tested?
- insulin aspart, biphasic insulin aspart 30 and insulin detemir
- How many people
- 3,809 participants
- Where
- 1 siteSlovakia
- Study dates
- Feb 2008to May 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Diabetes type 2
Who may be able to join
- Patients with type 2 diabetes
- Patients treated with human soluble insulin, NPH insulin or premixed human insulin
- Patients willing to sign informed consent
- Selection of study participants at the discretion of the physician
Who cannot join
- Subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30
- Subjects who were previously enrolled in this study
- Subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart) or Levemir® (Insulin Detemir) - for Treatment of Diabetes Mellitus
The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.
Full acronym for this study: COMMIT - CLEAN SWITCH
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Being tested
- insulin aspart, biphasic insulin aspart 30, insulin detemir
- Medical subject headings
- Diabetes Mellitus, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
insulin aspartDrug
Also called NovoRapid®
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
biphasic insulin aspart 30Drug
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
insulin detemirDrug
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
| Study group | Role | What they receive |
|---|---|---|
| A | Not described Receives: Drug: insulin aspart | |
| B | Not described Receives: Drug: biphasic insulin aspart 30 | |
| C | Not described Receives: Drug: insulin detemir |
What is being measured
The primary outcome is the main question the study is designed to answer.
Metabolic control measured as HbA1c
Measured: for the duration of the study
Secondary outcomes (8)
Percentage of subjects achieving HbA1c below 7.0% and below or equal 6.5%
Measured: after 12 weeks and 24 weeks
Change in FPG (glucose variability)
Measured: after 12 weeks and 24 weeks
Change in PPG (postprandial control)
Measured: after 12 weeks and 24 weeks
Change in insulin dose and number of injections
Measured: after 12 weeks and 24 weeks
Change in oral antidiabetic drug therapy
Measured: after 12 weeks and 24 weeks
Change in body weight
Measured: after 12 weeks and 24 weeks
Change in number of hypoglycaemic events during 4 weeks proceeding routine visits
Measured: after 12 weeks and 24 weeks
Number of adverse drug reactions (ADR)
Measured: after 12 weeks and 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2008 (estimated)
- Study startFeb 2008
- Primary completionMay 2010
- Study completionMay 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,809 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Global Clinical Registry (GCR, 1452), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00676741
- Sponsor's protocol ID
- BIASP-3516
- Acronym
- COMMIT
- Status last verified
- Oct 2016
- First submitted
- 9 May 2008
- Last updated
- 31 Oct 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart) or Levemir® (Insulin Detemir) - for Treatment of Diabetes Mellitus
- ClinicalTrials.gov ID
- NCT00676741
- Acronym / sponsor ID
- COMMIT / BIASP-3516
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,809 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- Feb 2008
- Primary completion
- May 2010 (actual)
- Study completion
- May 2010 (actual)
- First posted
- 13 May 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.
Full acronym for this study: COMMIT - CLEAN SWITCH
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| A | – | Drug: insulin aspart |
| B | – | Drug: biphasic insulin aspart 30 |
| C | – | Drug: insulin detemir |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Diabetes type 2
Key inclusion criteria (4 listed)
- Patients with type 2 diabetes
- Patients treated with human soluble insulin, NPH insulin or premixed human insulin
- Patients willing to sign informed consent
- Selection of study participants at the discretion of the physician
Key exclusion criteria (3 listed)
- Subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30
- Subjects who were previously enrolled in this study
- Subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| insulin aspartAlso: NovoRapid®Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation | Drug | A |
| biphasic insulin aspart 30Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation | Drug | B |
| insulin detemirStart dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation | Drug | C |
Primary outcome
Metabolic control measured as HbA1c
Time frame: for the duration of the study
8 secondary outcomes
Percentage of subjects achieving HbA1c below 7.0% and below or equal 6.5%
Time frame: after 12 weeks and 24 weeks
Change in FPG (glucose variability)
Time frame: after 12 weeks and 24 weeks
Change in PPG (postprandial control)
Time frame: after 12 weeks and 24 weeks
Change in insulin dose and number of injections
Time frame: after 12 weeks and 24 weeks
Change in oral antidiabetic drug therapy
Time frame: after 12 weeks and 24 weeks
Change in body weight
Time frame: after 12 weeks and 24 weeks
Change in number of hypoglycaemic events during 4 weeks proceeding routine visits
Time frame: after 12 weeks and 24 weeks
Number of adverse drug reactions (ADR)
Time frame: after 12 weeks and 24 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2016.
- Clinical Trials at Novo NordiskLink provided by the sponsor.
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Global Clinical Registry (GCR, 1452) study director
Novo Nordisk A/S
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes and Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 1 site in Slovakia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovakia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Metabolic control measured as HbA1c (time frame: for the duration of the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2016.